Skip to content
2000
image of Cholesterol-Lowering Effects of BMS-303141 Analogues via Inhibition of Adenosine Triphosphate-Citrate Lyase

Abstract

Background

Cholesterol is considered a major factor contributing to cardiovascular diseases. Statins, the most commonly prescribed cholesterol-lowering drugs, are known to have various limitations. Inhibition of Adenosine Triphosphate-Citrate Lyase (ACLY) has been proposed as an alternative therapeutic strategy for managing hypercholesterolemia by lowering cholesterol levels. This has led to the discovery of a cell-permeable small molecule ACLY inhibitor.

Methods

ACLY enzyme activity was assessed using an ACLY Assay Kit with the ADP-Glo Kinase Assay Kit. HepG2 cells were treated with test compounds to demonstrate cholesterol and fatty acid synthesis. Pharmacokinetic studies were performed on CD-1 mice following a single oral dose of the compounds. Hypercholesterolemia was induced in mice through a High-Fat and High Cholesterol Diet (HFHCD), and drugs were administered orally for six weeks. Serum and hepatic lipid profiles were subsequently analyzed.

Results

To increase the pharmacochemical properties, four analogues of BMS-303141, ID0018, ID0023, ID0085, and ID0106, were designed and synthesized. These compounds showed superior ACLY inhibitory activity and dose-dependent suppression of cholesterol and fatty acid synthesis in HepG2 cells. Among the analogues, ID0085 exhibited the most potent ACLY inhibition (IC: 45 nM, 10-fold lower than BMS-303141) and achieved near-complete suppression in cholesterol and fatty acid synthesis at the highest concentration. Pharmacokinetic studies revealed improved half-lives and systemic exposures for all analogues. 
In hypercholesterolemic mouse models, test compounds significantly reduced serum total cholesterol 
(32.0-57.3%) and low-density lipoprotein cholesterol (67.5-80.2%) levels compared to the vehicle group. Notably, ID0085 also increased high-density lipoprotein cholesterol levels.

Discussion

Among the synthesized analogues, ID0085 exhibited the most potent ACLY inhibition, superior pharmacokinetic properties, and significant improvements in both serum and hepatic cholesterol profiles compared to BMS-303141.

Conclusion

Based on the results, ID0085 appears to be the most promising therapeutic candidate for the treatment of hypercholesterolemia.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128387531250713164724
2025-08-04
2025-11-04

  • From This Site

    /content/journals/cpd/10.2174/0113816128387531250713164724
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hokanson J.E. Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 1996 3 2 213 219 10.1097/00043798‑199604000‑00014 8836866
    [Google Scholar]
  2. Sun J. Qiao Y. Zhao M. Magnussen C.G. Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries/territories, 1990–2019: A systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023 21 1 222 10.1186/s12916‑023‑02925‑4 37365627
    [Google Scholar]
  3. Cardiovascular diseases (CVDs) 2023 Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  4. Chareonrungrueangchai K. Wongkawinwoot K. Anothaisintawee T. Reutrakul S. Dietary factors and risks of cardiovascular diseases: An umbrella review. Nutrients 2020 12 4 1088 10.3390/nu12041088 32326404
    [Google Scholar]
  5. Xie N. Cui Y. Yin Y.N. Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. BMC Complement. Altern. Med. 2011 11 1 53 10.1186/1472‑6882‑11‑53 21722398
    [Google Scholar]
  6. Dunn-Emke S. Weidner G. Ornish D. Benefits of a low-fat plant-based diet. Obes. Res. 2001 9 11 731 10.1038/oby.2001.100 11707542
    [Google Scholar]
  7. Ahn C.H. Choi S.H. New drugs for treating dyslipidemia: Beyond statins. Diabetes Metab. J. 2015 39 2 87 94 10.4093/dmj.2015.39.2.87 25922802
    [Google Scholar]
  8. Banach M. Serban M.C. Discussion around statin discontinuation in older adults and patients with wasting diseases. J. Cachexia Sarcopenia Muscle 2016 7 4 396 399 10.1002/jcsm.12109 27030814
    [Google Scholar]
  9. Banach M. Rizzo M. Toth P.P. Statin intolerance – An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin. Drug Saf. 2015 14 6 935 955 10.1517/14740338.2015.1039980 25907232
    [Google Scholar]
  10. Xu S. Luo S. Zhu Z. Xu J. Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur. J. Med. Chem. 2019 162 212 233 10.1016/j.ejmech.2018.11.011 30448414
    [Google Scholar]
  11. Lamb Y.N. Rosuvastatin/Ezetimibe: A review in hypercholesterolemia. Am. J. Cardiovasc. Drugs 2020 20 4 381 392 10.1007/s40256‑020‑00421‑1 32648167
    [Google Scholar]
  12. Penson P. McGowan M. Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin. Investig. Drugs 2017 26 2 251 259 10.1080/13543784.2017.1280458 28064554
    [Google Scholar]
  13. Burke A.C. Telford D.E. Huff M.W. Bempedoic acid: Effects on lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol. 2019 30 1 1 9 10.1097/MOL.0000000000000565 30586346
    [Google Scholar]
  14. Morrow M.R. Batchuluun B. Wu J. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab. 2022 34 6 919 936.e8 10.1016/j.cmet.2022.05.004 35675800
    [Google Scholar]
  15. Pinkosky S.L. Newton R.S. Day E.A. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat. Commun. 2016 7 1 13457 10.1038/ncomms13457 27892461
    [Google Scholar]
  16. Samsoondar J.P. Burke A.C. Sutherland B.G. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr−/− mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler. Thromb. Vasc. Biol. 2017 37 4 647 656 10.1161/ATVBAHA.116.308963 28153881
    [Google Scholar]
  17. Bilen O. Ballantyne C.M. Bempedoic acid (ETC-1002): An investigational inhibitor of ATP citrate lyase. Curr. Atheroscler. Rep. 2016 18 10 61 10.1007/s11883‑016‑0611‑4 27663902
    [Google Scholar]
  18. Brandts J. Ray K.K. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat. Rev. Cardiol. 2023 20 9 600 616 10.1038/s41569‑023‑00860‑8 37055535
    [Google Scholar]
  19. Ferri N. Corsini A. Mechanism of bempedoic acid induced cholelithiasis: A role for statins to limit this adverse effect? Pharmacol. Res. 2023 196 106900 10.1016/j.phrs.2023.106900 37652280
    [Google Scholar]
  20. Li J.J. Wang H. Tino J.A. 2-Hydroxy-N-arylbenzene-sulfonamides as ATP-citrate lyase inhibitors. Bioorg. Med. Chem. Lett. 2007 17 11 3208 3211 10.1016/j.bmcl.2007.03.017 17383874
    [Google Scholar]
  21. Mašek J. Fábry P. High-fat diet and the development of obesity in albino rats. Experientia 1959 15 11 444 445 10.1007/BF02157708 14421993
    [Google Scholar]
  22. Dumas L.S. Briand F. Clerc R. Evaluation of antiatherogenic properties of ezetimibe using 3H-labeled low-density-lipoprotein cholesterol and 99mTc-cAbVCAM1-5 SPECT in ApoE−/− mice fed the paigen diet. J. Nucl. Med. 2017 58 7 1088 1093 10.2967/jnumed.116.177279 28280218
    [Google Scholar]
  23. Wang Q. He Y. Li X. Lactobacillus reuteri CCFM8631 alleviates hypercholesterolaemia caused by the paigen atherogenic diet by regulating the gut microbiota. Nutrients 2022 14 6 1272 10.3390/nu14061272 35334930
    [Google Scholar]
  24. Wei J. Leit S. Kuai J. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature 2019 568 7753 566 570 10.1038/s41586‑019‑1094‑6 30944472
    [Google Scholar]
  25. Lawrie A. Hameed A.G. Chamberlain J. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am. J. Pathol. 2011 179 4 1693 1705 10.1016/j.ajpath.2011.06.037 21835155
    [Google Scholar]
  26. Pinkosky S.L. Filippov S. Srivastava R.A.K. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res. 2013 54 1 134 151 10.1194/jlr.M030528 23118444
    [Google Scholar]
  27. Folch J. Lees M. Stanley G.H.S. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957 226 1 497 509 10.1016/S0021‑9258(18)64849‑5 13428781
    [Google Scholar]
  28. Islam S.M.T. Osa-Andrews B. Jones P.M. Muthukumar A.R. Hashim I. Cao J. Methods of low-density lipoprotein-cholesterol measurement: Analytical and clinical applications. EJIFCC 2022 33 4 282 294 36605300
    [Google Scholar]
  29. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 2008 263 3 256 273 10.1111/j.1365‑2796.2007.01898.x 18271871
    [Google Scholar]
  30. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr. Opin. Lipidol. 2010 21 4 305 311 10.1097/MOL.0b013e32833b7756 20531184
    [Google Scholar]
  31. Nemes K. Åberg F. Gylling H. Isoniemi H. Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications. World J. Hepatol. 2016 8 22 924 932 10.4254/wjh.v8.i22.924 27574546
    [Google Scholar]
  32. de La Serre C.B. Ellis C.L. Lee J. Hartman A.L. Rutledge J.C. Raybould H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010 299 2 G440 G448 10.1152/ajpgi.00098.2010 20508158
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128387531250713164724
Loading
Cholesterol-Lowering Effects of BMS-303141 Analogues via Inhibition of Adenosine Triphosphate-Citrate Lyase
Bentham Science Publishers ; https://doi.org/10.2174/0113816128387531250713164724
/content/journals/cpd/10.2174/0113816128387531250713164724
/content/journals/cpd/10.2174/0113816128387531250713164724
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: adenosine triphosphate-citrate lyase inhibitor ; BMS-303141 ; high-fat and high-cholesterol diet ; HepG2 cell ; Hypercholesterolemia ; Bempedoic acid

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test